What is B. Riley’s Estimate for Geron FY2027 Earnings?

Geron Co. (NASDAQ:GERN) – Stock analysts at B. Riley lowered their FY2027 earnings per share estimates for shares of Geron in a report issued on Tuesday, February 18th. B. Riley analyst K. Patel now expects that the biopharmaceutical company will earn $0.28 per share for the year, down from their previous forecast of $0.36. B. Riley currently has a “Buy” rating and a $3.50 price target on the stock. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share.

Other equities research analysts have also issued reports about the stock. Barclays raised shares of Geron to a “strong-buy” rating in a report on Friday, November 29th. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price target on shares of Geron in a report on Tuesday, December 10th. Finally, Needham & Company LLC upped their price target on shares of Geron from $6.00 to $7.00 and gave the company a “buy” rating in a report on Monday, January 13th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Geron presently has a consensus rating of “Moderate Buy” and a consensus target price of $6.91.

Geron Price Performance

NASDAQ:GERN opened at $2.54 on Wednesday. Geron has a one year low of $1.64 and a one year high of $5.34. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89. The firm has a market cap of $1.54 billion, a price-to-earnings ratio of -7.94 and a beta of 0.53. The firm’s fifty day moving average is $3.16 and its two-hundred day moving average is $3.89.

Institutional Investors Weigh In On Geron

Several hedge funds have recently modified their holdings of the company. GF Fund Management CO. LTD. purchased a new stake in shares of Geron during the 4th quarter worth about $45,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Geron by 24.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,267,176 shares of the biopharmaceutical company’s stock worth $4,486,000 after purchasing an additional 246,433 shares during the last quarter. Woodline Partners LP raised its position in shares of Geron by 64.6% during the 4th quarter. Woodline Partners LP now owns 11,587,344 shares of the biopharmaceutical company’s stock worth $41,019,000 after purchasing an additional 4,549,031 shares during the last quarter. Velan Capital Investment Management LP acquired a new position in shares of Geron during the 4th quarter worth about $173,000. Finally, Vestal Point Capital LP raised its position in shares of Geron by 947.6% during the 4th quarter. Vestal Point Capital LP now owns 11,000,000 shares of the biopharmaceutical company’s stock worth $38,940,000 after purchasing an additional 9,950,000 shares during the last quarter. 73.71% of the stock is owned by hedge funds and other institutional investors.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.